Global  

Celebrating 10 Years of Trusted News Discovery
One News Page
> >

Coherus BioSciences Announces New Employment Inducement Grants

GlobeNewswire Monday, 14 January 2019
REDWOOD CITY, Calif., Jan. 14, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that effective January 10, 2019, the compensation committee of the company’s board of directors granted three new employees options to purchase an aggregate of 68,000 shares of the company’s common stock with a per share exercise price of $12.20, the closing trading price on the grant date. The stock options were granted pursuant to the Coherus BioSciences, Inc. 2016 Employment Commencement Incentive Plan, which was approved by the company’s board of directors in June 2016 under Rule 5635(c)(4) of the Nasdaq Global Select Market for equity grants to induce new employees to enter into employment with the company.*About Coherus BioSciences, Inc.*

Coherus is a leading biosimilar company that develops and commercializes high-quality therapeutics for major regulated markets. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. Composed of a team of proven industry veterans with world-class expertise in process science, analytical characterization, protein production, sales and marketing and clinical-regulatory development, Coherus is positioned as a leader in the global biosimilar marketplace. Coherus has received regulatory approval for UDENYCA™ (pegfilgrastim-cbqv) in the U.S. and European Union and is advancing two late-stage clinical products towards commercialization, CHS-1420 (adalimumab biosimilar) and CHS-0214 (etanercept biosimilar), and developing a robust pipeline of future products in ophthalmology (including CHS-3351, a ranibizumab biosimilar, and CHS-2020, an aflibercept biosimilar), as well as CHS-131, a small molecule for nonalcoholic steatohepatitis (NASH) and multiple sclerosis. For additional information, please visit www.coherus.com.

CONTACT:

David S. Arrington
VP, Investor Relations & Corporate Affairs
Coherus BioSciences, Inc.
darrington@coherus.com
+1 (650) 395-0196            
0
shares
ShareTweetSavePostSend
 

You Might Like


Recent related news from verified sources

Law supporting domestic violence victims start of new employment era: lawyer

Law supporting domestic violence victims start of new employment era: lawyer
An employment lawyer says New Zealand is entering new territory as the Government prepares to roll out a new law to benefit domestic violence victims. From April...
New Zealand Herald

New Zealand February job openings up 0.9% – Ministry of Business, Innovation and Employment

Early Wednesday, New Zealand’s Ministry of Business, Innovation and Employment (MBIE) released results of the economy’s government official employment market...
FXstreet.com


Other recent news in Press Releases

Sonata SOFTWARE Makes Strategic Investment in Retail10X, a Silicon Valley-based Retail AI SOFTWARE-as-service Platform CompanyTransCanna Receives Third Party BUSINESS Valuation of US$50 million - $75 million Range for Facility Acquisition
NutraLife Biosciences Encouraged By CVS HEALTH Corporation's Decision to Distribute CBD at 800 Stores in the U.S.Marriott Bonvoy Announces A Series of New Lifestyle, ENTERTAINMENT and Sport Experiences in Asia Pacific
Environmentally friendly: One News Page is hosted on servers powered solely by renewable energy
© 2019 One News Page Ltd. All Rights Reserved.
About us  |  Contact us  |  Disclaimer  |  Press Room  |  Terms & Conditions  |  Content Accreditation
 RSS  |  News for my Website  |  Free news search widget  |  In the News  |  DMCA / Content Removal  |  Privacy & Data Protection Policy
How are we doing? FeedbackSend us your feedback  |   LIKE us on Facebook   FOLLOW us on Twitter  •  FOLLOW us on Pinterest
One News® is a registered trademark of One News Page Ltd.